Predictive validity and immune cell involvement in the pathogenesis of piroxicam-accelerated colitis in interleukin-10 knockout mice
- 1 July 2014
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 21 (1) , 137-147
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 52 references indexed in Scilit:
- Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse — A model mimicking inflammatory bowel diseaseJournal of Crohn's and Colitis, 2014
- Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in miceInternational Immunopharmacology, 2013
- Liposomes for Specific Depletion of Macrophages from Organs and Tissues2009
- Therapeutic benefit of pentostatin in severe IL-10−/− ColitisInflammatory Bowel Diseases, 2008
- A crucial role for macrophages in the pathology of K/B × N serum‐induced arthritisEuropean Journal of Immunology, 2005
- Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel diseaseClinical Immunology, 2005
- Development and validation of a novel IL-10 deficient cell transfer model for colitisInternational Immunopharmacology, 2005
- Refined histopathologic scoring system improves power todetect colitis QTL in miceMammalian Genome, 2004
- Selected summary: Feagan BG, McDonald JWD, Rochon J, et al. for the Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846–1851 (June)Gastroenterology, 1995
- Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporinDigestive Diseases and Sciences, 1993